Key result
Transcatheter mitral repair devices, particularly MitraClip, offer promising alternatives for correcting mitral regurgitation in patients at high risk for surgery.
Why the study?
While most safety and efficacy evidence for percutaneous mitral repair comes from MitraClip, new transcatheter alternatives have emerged.
This review provides an overview of current and emerging transcatheter mitral repair devices for patients with mitral regurgitation at high surgical risk.
Emerging transcatheter MR devices show promise beyond MitraClip; leaves open their comparative role pending randomized data.
Mitral regurgitation (MR) is the second most common valvular heart disease and its prevalence is increasing with population ageing. In the recent years we have witnessed the development of several transcatheter devices to correct MR in patients at high-risk for surgery. The majority of evidence regarding safety and efficacy of this new therapy comes from MitraClip studies. However, new alternatives on the field of valve repair have emerged with promising results. The aim of this review is to portrait the landscape of transcatheter mitral repair alternatives, from currently used devices to those that will have a role in the near future.
No takes yet. Share an insight, caveat, or question.
Estévez‐Loureiro et al. (2020) conducted a review in Mitral regurgitation. Transcatheter mitral repair devices was evaluated. Transcatheter mitral repair devices, particularly MitraClip, offer promising alternatives for correcting mitral regurgitation in patients at high risk for surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: